Prescription of anxiolytics, sedatives, hypnotics and antidepressants in outpatient, universal care during the COVID-19 pandemic in Portugal: a nationwide, interrupted time-series approach

Marta Estrela, Tânia Magalhães Silva, Eva Rebelo Gomes, Maria Piñeiro, Adolfo Figueiras, Fátima Roque, Maria Teresa Herdeiro

ABSTRACT

Background The COVID-19 pandemic has had a significant impact on the population’s mental health. However, its impact on the consumption of anxiolytics, sedatives, hypnotics and antidepressants remains to be evaluated. Hence, this article aims to assess the prescription trends of these drugs in Portugal, from January 2018 to March 2021, while critically examining whether the COVID-19 pandemic had an impact on these prescription trends or not.

Methods A nationwide interrupted time-series analysis of the prescription data of anxiolytics, sedatives, hypnotics and antidepressants in outpatient setting of the public health sector was conducted. The data encompassed the defined daily dose per month, age range and sex and were analysed following a segmented regression approach.

Results The pandemic preceded an immediate reduction in the prescription of anxiolytics, sedatives and hypnotics for children and adolescents. However, an increasing trend throughout the pandemic has been noted in the prescription of these drugs, especially among adults aged 65 years or above. A drop in antidepressant prescription was observed as an immediate effect of the pandemic among male and female adolescents and elderly women. From March 2020 to March 2021, a decreasing prescription trend has been noted among men.

Conclusions When analysing specific genders and age ranges, differences can be noted, in terms of both immediate impact and prescribing trends throughout 1 year of the COVID-19 pandemic. The impact of the pandemic on mental health and its association with the consumption trends of psychoactive drugs, and with the access to mental health treatments, should be further assessed.

INTRODUCTION

Since 31 December 2019, the COVID-19 epidemic has escalated and quickly spread around the world. The WHO formally declared the existence of a pandemic in March 2020, with the first confirmed case in Portugal occurring on 2 March 2020. Portugal was one of the countries that adopted earlier containment measures, reaching a peak in the number of newly confirmed cases on 10 April 2020 while always presenting lower fatality rates than the European average. The declaration of the state of emergency in Portugal was decreed on 18 March, along with several measures to reduce the risk of contracting and transmitting COVID-19, such as closing university campuses, prohibiting large gatherings and announcing mandatory confinement at home. The WHO formally declared the existence of a pandemic in March 2020, with the first confirmed case in Portugal occurring on 2 March 2020, reaching a peak of incidence on 19 November, with a 7-day rolling average incidence of 630 cases/1 000 000 inhabitants. After a slight reduction in the number of cases during November–December 2020, a third wave followed during January 2021, reaching an unprecedented incidence of COVID-19 cases, with a 7-day rolling average of 1264 cases/1 000 000 inhabitants.

Further than the stresses characteristic of the illness itself, mass home-confinement directives were unprecedented, raising concerns about their impact on the population. The increase in mental distress and mental disorders may have occurred not only among those who suffered from COVID-19 but also among quarantined people in general and health practitioners. People with mental health disorders are generally more susceptible to infection during epidemics, and it appears that there is a bidirectional association between psychiatric disorders and COVID-19. Psychiatric disorders appear to be an independent risk factor for COVID-19, and survivors of COVID-19 disease are at an increased risk of psychiatric sequelae. A recent US study reported a rise in antidepressant, anti-anxiety and anti-insomnia drug prescription since the reporting of the first COVID-19 cases in mid-February 2020, peaking on the second week of March, when COVID-19 was declared a pandemic by the WHO.

In Portugal, mental disorders are associated with one of the highest societal costs in high-income countries, causing more than 20% of unproductive days. Yet, despite the high prevalence of these disorders, the period between the disease onset and the initiation of therapy remains concerning. Furthermore, poor access to prompt non-pharmacological therapy within
the Portuguese National Health System (NHS) may explain the increasing consumption of anxiolytics, sedatives, hypnotics and antidepressants.12

As women and elders tend to be more vulnerable to common mental health disorders, such as depression and anxiety, they are among the groups that most consume anxiolytics, sedatives, hypnotics and antidepressants.10 12 During the COVID-19 pandemic, women and adolescents were shown to be among the most vulnerable groups in terms of mental health, while older adults have experienced a slight improvement in their mental health during the first months of the pandemic.13-17 The main objectives of this study are to (1) evaluate the prescription trends of anxiolytics, sedatives, hypnotics and antidepressants, in outpatient setting in Portugal, from January 2018 to March 2021 and to (2) verify whether the COVID-19 pandemic had an impact on the aforementioned prescription trends.

MATERIALS AND METHODS

Setting
Portugal has a population of around 10.3 million inhabitants,18 unevenly distributed, with a high incidence in the metropolitan areas of Lisbon and Oporto. The NHS is a universal tax-financed system tendentially free-of-charge covering all residents in Portugal.19 The NHS does not cover all prescribed medication. Antidepressants, anxiolytics, sedatives and hypnotics are subject to variable patient coinsurance with a co-payment rate of 37% of the price, corresponding to non-priority medicines with proven therapeutic value,20 and are dispensed in pharmacies only when a medical prescription is presented.19

Study design and data collection
We used an uncontrolled interrupted time-series (ITS) design with monthly data, from January 2018 to March 2021.21 This design allows for effects to be estimated by controlling for baseline levels and trends. The data concerning drug prescription were obtained from the System of Information and Monitoring of the Portuguese NHS public-access platform, between January 2018 and March 2021. This platform was developed by the shared services of the Health Ministry (Serviços Partilhados do Ministério da Saúde) and aims to strengthen, integrate and aggregate medical/health data on a national scale.22 As the platform included the prescription by several institutions, the following were excluded: health institutions associated with Ministries other than the Health Ministry, administrative institutions of the National Health Service and addiction rehabilitation centres.

The data on prescription collected comprised the monthly defined daily dose (DDD) of anxiolytics, sedatives and hypnotics, and antidepressants (Anatomical Therapeutic Chemical (ATC) codes N05B, N05C and N06A, respectively) prescribed in outpatient settings by physicians of the public health sector (including hospitals, hospitals centres and primary care centres/units), across the period January 2018 to March 2021. Data were stratified by sex and age range. Although the United Nations and the WHO defined specific age ranges, the database only allowed the stratification by the following intervals: 0–7 years old (childhood), 8–17 (adolescence), 18–64 (adults), 65–74 (older adulthood) and 75+ (elderly).2024 The target drugs of this study were the classes corresponding to the ATC codes N05B (anxiolytics), N05C (sedatives and hypnotics) and N06A (antidepressants). At the same time, at the national level, there is also a pharmacotherapeutic classification. This classification of medicines is carried out based on a systematisation grouped according to their identity and the therapeutic indications for which they are approved and authorised.25 As the national drug classification merges N05B and N05C into one category, the data obtained are then presented into two main variables: anxiolytics, sedatives and hypnotics (N05B+N05C), and antidepressants (N06A). This study is reported as per the Reporting of studies Conducted using Observational Routinely collected health Data statement26 (see online supplemental material S1).

Statistical analysis
An ITS analysis model based on a segmented regression approach27–29 was designed to analyse the differences between the monthly prescribed DDDs of anxiolytics, sedatives, and hypnotics and antidepressants. A segmented linear regression analysis model30 was designed to analyse the differences observed between March 2020 and March 2021, in terms of prescribed drugs. For statistical analysis purposes, we constructed a segmented regression model of the ITS for each outcome analysed: monthly prescribed DDDs of (1) anxiolytics, sedatives and hypnotics and (2) antidepressants. The independent variables were defined as follows: time (t: 1, 2, 3,…, 39), a binary variable (COVID-19) taking values of ‘0’ before March 2020 and ‘1’ since March 2020, corresponding to the time in which the effect of the pandemic is measured, and a variable for the time elapsed since the first COVID-19 case, which took the value of ‘0’ before and values of ‘1’, ‘2’, ‘3’, …, corresponding to the months from March 2020 to March 2021. To identify possible seasonal changes in antibiotic prescribing, the X-13 ARIMA (autoregressive integrated moving average)-SEATS procedure was applied.31 This method is an adaptation of the US Bureau of the Census X-13-ARIMA model that produces a seasonally adjusted time-series. The Cumby-Huizinga test was used to check for autocorrelation (10 lags of autocorrelation were tested). Based on the results of these tests, we introduced lags of the dependent variable to correct for autocorrelation. Sensitivity analyses that vary the timing of pandemic interruption in plus and minus a month for all ITS models were performed. This analysis allows to see how coefficients change and the robustness of the results. The normality of the outcomes was confirmed by the Kolmogorov-Smirnov test (p>0.1). All analyses were performed using the free R statistical software environment (V.4.0.5),12 except the Cumby-Huizinga test that was carried out with Stata V.12.32

RESULTS

Prescription trends of anxiolytics, sedatives, hypnotics and antidepressants
When analysing the prescription trends of anxiolytics, sedatives and hypnotics throughout January 2018 to March 2021, no significant alterations have been noted in any of the groups considered. On the contrary, apart from children, all other groups revealed a significant increase in the prescription of antidepressants throughout the period under study (see online supplemental material S2).

The impact of the COVID-19 pandemic on the prescription of anxiolytics, sedatives and hypnotics
Figure 1 displays the prescription tendencies among male and female patients. A sharp decline can be noticed at the beginning of the pandemic. However, when considering the period from March 2020 to March 2021, an increasing tendency is observed. The prescription of these drugs has
remained almost three times higher among female patients compared to male patients after the beginning of the pandemic.

The results displayed in table 1 show a significant, immediate reduction in the prescription of anxiolytics, sedatives and hypnotics on male and female children (B = −3795.81 and B = −2938.74, respectively), adolescents (B = −2899.09 and B = −7142.78, respectively) and elderly women (B = −330 938.28). In terms of relative change, a drop in the prescription of these drugs by almost 50% has been noted among children, and a decrease by 10.57% and 27.46% has been observed among male and female adolescents, respectively. No immediate impact has been observed on any other group. However, an overall increasing prescription trend has been noted throughout the COVID-19 pandemic (B = 185 245.64), especially among male and female older adults (B = 13 162.11 and B = 40 328.93, respectively) and the elderly (B = 14 582.46 and B = 55 986.34, respectively). The adjusted coefficients are presented in the supplementary material (see online supplemental material S2).

The impact of the COVID-19 pandemic on the prescription of antidepressants

The figure 2 displays the prescription tendencies among male and female patients. Until the beginning of the pandemic, an increasing trend was observed but since then, a decreasing tendency was apparent. Again, the prescription of these drugs is more than three times higher among female patients compared to male patients.

A significant, immediate impact of the COVID-19 pandemic on prescription of antidepressants has been noted among male and female adolescents (B = −9808.52 and B = −20 817.58, respectively) and elderly women (B = −293 440.34), as shown in table 2. However, when analysing the relative change a month after the pandemic emerged, the children and adolescent groups have experienced the most pronounced drop in the prescription of antidepressants, ranging from 8% to 23%. During the period corresponding to March 2020 to March 2021, a decreasing trend can be noted in male adolescents (B = −2313.24), adults (B = −37 988.11), older adults (B = −18 402.10) and the elderly (B = −17 232.59). No significant impact of the COVID-19 pandemic has

Table 1  Segmented regression of time-series results expressed in defined daily doses—prescription of anxiolytics, sedatives and hypnotics

<table>
<thead>
<tr>
<th></th>
<th>Immediate impact</th>
<th>Change in trend</th>
<th>Absolute change in outcome a month after COVID-19</th>
<th>Relative change in outcome a month after COVID-19 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>B</td>
<td>95% CI</td>
<td>B</td>
<td>95% CI</td>
</tr>
<tr>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Children (≥7 yo)</td>
<td>−3795.81*</td>
<td>−5361.47 to −2230.15</td>
<td>−0.36</td>
<td>−179.70 to 178.99</td>
</tr>
<tr>
<td>Adolescents (8–17 yo)</td>
<td>−2899.09*</td>
<td>−5673.12 to −125.05</td>
<td>122.73</td>
<td>−188.30 to 433.77</td>
</tr>
<tr>
<td>Adults (18–64 yo)</td>
<td>−168 291.27</td>
<td>−439 366.75 to 102 784.21</td>
<td>27129.40</td>
<td>−3468.68 to 57 727.48</td>
</tr>
<tr>
<td>Older adults (65–74 yo)</td>
<td>−34 403.70</td>
<td>−100 896.53 to 32 089.14</td>
<td>13 162.11*</td>
<td>4929.03 to 21 395.18</td>
</tr>
<tr>
<td>Elderly (≥75 yo)</td>
<td>−30 939.04</td>
<td>−94 317.29 to 24 339.20</td>
<td>14 582.46*</td>
<td>6863.67 to 22 301.26</td>
</tr>
<tr>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Children (≥7 yo)</td>
<td>−2938.74*</td>
<td>−3966.10 to −1911.38</td>
<td>−26.05</td>
<td>−133.60 to 81.50</td>
</tr>
<tr>
<td>Adolescents (8–17 yo)</td>
<td>−7142.78*</td>
<td>−12 399.81 to −1885.75</td>
<td>521.04</td>
<td>−5.99 to 1048.07</td>
</tr>
<tr>
<td>Adults (18–64 yo)</td>
<td>−80 580.27</td>
<td>−676 807.98 to 515 647.44</td>
<td>45 887.32</td>
<td>−23 833.17 to 115 607.81</td>
</tr>
<tr>
<td>Older adults (65–74 yo)</td>
<td>−186 383.98</td>
<td>−374 446.64 to 1678.67</td>
<td>40 328.92*</td>
<td>17 743.87 to 62 913.98</td>
</tr>
<tr>
<td>Elderly (≥75 yo)</td>
<td>−330 938.28*</td>
<td>−516 988.89 to −144887.66</td>
<td>55 986.34*</td>
<td>34 033.34 to 77 939.34</td>
</tr>
<tr>
<td>Total</td>
<td>−724 445.94</td>
<td>−1 881 469.52 to 432 577.63</td>
<td>185 245.64*</td>
<td>40 314.44 to 330 176.85</td>
</tr>
</tbody>
</table>

The impact of the COVID-19 pandemic on the prescription of antidepressants

*p<0.05
been observed in the prescription of antidepressants among female patients. The adjusted coefficients are presented in the supplementary material (see online supplemental material S3).

Sensitivity analysis
The results of the sensitivity analysis are presented in Supplemental Material (see online supplemental materials 4 and 5). All specifications show very similar results, despite slight changes in magnitude and statistical significance in some coefficients; hence, the conclusions inferred from the obtained results remain unchanged.

DISCUSSION
To our knowledge, this is the first study concerning the prescription of anxiolytics, sedatives, hypnotics and antidepressants within the Portuguese NHS throughout 1 year of the COVID-19 pandemic using IHS.

Main results
The COVID-19 pandemic has preceded an immediate reduction in the prescription of anxiolytics, sedatives and hypnotics, especially among children, adolescents and elderly women. Furthermore, a reduction in antidepressant prescription has also been noted among adolescents and elderly women. Throughout the period of the COVID-19 pandemic, statistically significant decreases were observed in the prescription of antidepressants among male patients. On the contrary, significant increasing trends in the prescription of anxiolytics, sedatives and hypnotics were observed among women aged 65 years or above. Thus, an amplification of the discrepancies in prescription between male and female patients has been observed.

Prescription of anxiolytics, sedatives and hypnotics
A significant decrease in the prescription of anxiolytics, sedatives and hypnotics for children and adolescents was noted. This might be a result of the decreased number of doctor visits during the first months of the COVID-19 pandemic, as these drugs are only provided through medical prescription. Yet, careful considerations should be made when associating these decreasing trends with the mental state of children and adolescents during the COVID-19 pandemic, as recent literature reports increasing mental distress on these populations and a doubling of prevalence rates of anxiety and depressive symptoms, as a result of the disruption of routines, social distancing and confinement. Thus, the decreasing consumption of these drugs does not reflect the increasingly damaged mental health of younger people, which raises concerns regarding access to paediatric mental healthcare during the pandemic, especially among girls.

A sharp reduction in the prescription of these drugs has been also observed as an immediate impact of the COVID-19 pandemic among elderly women, which, along with the decreasing number of doctor visits, might be associated with the improvement—or stabilisation—of the mental state of older adults during the first months of the COVID-19 pandemic. However, an increasing trend has been noted among older adults and the elderly throughout 1 year of the COVID-19 pandemic, which, despite the short-term resilience of these patients, highlights the concerns regarding the long-term impact on the mental health of patients aged 65 years or above.

Antidepressant prescription
Although an increasing trend in the prescription of antidepressants can be noted throughout the period prior to the pandemic, an immediate decrease in prescription is noted among adolescents and elderly women, which, similar to the prescription of anxiolytics, sedatives and hypnotics, might be associated with the decreased number of doctor visits and improvement in the mental health of the elderly. A significant decreasing tendency has been observed since the COVID-19 pandemic began among male patients. No significant changes during this period have been noted on female patients. This
declining trend throughout the pandemic months among men might be a reflex of the slow returning to previous tendencies and loosening of containment measures.\(^5\) Yet, increasing prescription tendencies of antidepressants before the beginning of the pandemic were observed, and increasing mental distress during the pandemic has been reported.\(^4\)\(^6\)\(^40\) especially among women.\(^4\)\(^5\)\(^16\)\(^41\) Hence, our results might incite reflection on whether the pandemic has been an obstacle for the treatment of mental health-related concerns has been reported.\(^32\)\(^43\)

**CONCLUSIONS**

As these results offer an overview of the impact of the pandemic from a pharmacoepidemiological standpoint, it is now important to assess whether the prescription of anxiolytics, sedatives and hypnotics, as well as of antidepressants, is related to an impact on mental health disorders from a clinical standpoint. Despite our results, the mental health of the population should be carefully monitored, for instance, with measures to tackle the impact of the pandemic on the mental health of the population, especially considering previous reports pointing to a rise in the incidence of mental health disorders on COVID-19 emergence.\(^44\)

Further studies could complement the results obtained with the follow-up of future prescription trends.

**Author affiliations**

1IBiMED - Institute of Biomedicine - Department of Medical Sciences, University of Aveiro, Aveiro, Portugal
2Allergy and Clinical Immunology Service, University Hospital Center of Porto, Porto, Portugal
3Consortium for Biomedical Research in Epidemiology & Public Health (CIBER en Epidemiología y Salud Pública—CIBERESP), University of Santiago de Compostela, Santiago de Compostela, Spain
4Institute of Health Research of Santiago de Compostela, Santiago de Compostela, Spain
5Research Unit for Inland Development, Guarda Polytechnic Institute, Guarda, Portugal
6Health Sciences Research Centre, University of Beira Interior, Covilhã, Castelo Branco, Portugal

**Twitter** Marta Estrela @martar_estrela

**Contributors** TH, FR and AF were involved in conceptualisation; ME, TMS, EG, MP-L, FR, TH and AF in methodology; ME, TMS, MP-L and AF in software; TH, FR, AF and EG in validation; ME, AF, FR and TH in formal analysis; ME in writing—original draft preparation; ME, TMS, EG, MP-L, AF, FR and TH in writing—review and editing; ME, TMS, EG, MP-L, AF, FR and TH in visualisation; TH, AF and FR in supervision; and TH and FR in project administration. All authors have read and agreed to the published version of the manuscript.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient consent for publication** Not applicable.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available in a public, open access repository.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

**ORCID iDs**

Marta Estrela http://orcid.org/0000-0001-6123-3818
Tânia Magalhães Silva http://orcid.org/0000-0003-2914-3120
Eva Rebelo Gomes http://orcid.org/0000-0001-8956-9145
Adolfo Figueiras http://orcid.org/0000-0002-5766-8672
Fátima Roque http://orcid.org/0000-0003-0169-3788
Maria Teresa Herdeiro http://orcid.org/0000-0002-0500-4049

**REFERENCES**

Original research


21 WHO. Medicines reimbursement policies in Europe, 2018.


